Inactive Instrument

Analyst Reco. Heron Therapeutics Inc OTC Bulletin Board

Equities

Capital One Starts Heron Therapeutics With Overweight Rating, $6 Price Target	Apr. 23	MT
Needham Adjusts Price Target on Heron Therapeutics to $5 From $4, Keeps Buy Rating	Mar. 13	MT
Needham Trims Price Target on Heron Therapeutics to $4 From $5, Keeps Buy Rating	Nov. 15	MT
Needham Adjusts Price Target on Heron Therapeutics to $5 From $6, Maintains Buy Rating	23-07-25	MT
Needham Adjusts Heron Therapeutics' Price Target to $6 From $7, Keeps Buy Rating	23-05-12	MT
Needham Adjusts Price Target on Heron Therapeutics to $6 From $7, Maintains Buy Rating	23-05-12	MT
Evercore ISI Adjusts Price Target on Heron Therapeutics to $10 From $15, Maintains Outperform Rating	23-03-24	MT
Needham Adjusts Price Target on Heron Therapeutics to $7 From $8, Keeps Buy Rating	23-03-24	MT
Needham Trims Price Target on Heron Therapeutics to $8 From $10, Maintains Buy Rating	22-11-09	MT
Cantor Fitzgerald Adjusts Price Target for Heron Therapeutics to $12 From $20, Maintains Overweight Rating	22-05-10	MT
Needham Adjusts Heron Therapeutics' Price Target to $14 from $16, Keeps Buy Rating	22-05-10	MT
Cowen & Co Adjusts Heron Therapeutics Price Target to $13 From $31, Maintains Outperform Rating	22-03-01	MT
Needham & Co Adjusts Heron Therapeutics Price Target to $16 From $24, Maintains Buy Rating	22-03-01	MT
HERON THERAPEUTICS : Stifel Adjusts Heron Therapeutics' Price Target to $25 from $20, Keeps Buy Rating	21-01-05	MT
HERON THERAPEUTICS : SVB Leerink Adjusts Heron Therapeutics' Price Target to $24 From $21, Keeps at Outperform	20-12-02	MT

No results for this search